CryoFluor Therapeutics Closes Additional Investment.TUCSON, Ariz. -- CryoFluor Therapeutics, a medical-device company developing a novel cryosurgical technology platform, has received an additional investment that extends its second round of financing. The additional funds will allow the company to complete a feasibility clinical trial of its device to treat abnormal uterine bleeding uterine bleeding Abnormal bleeding from the uterus not related to menstruation. Most common in the first few years after menarche and as menopause approaches, it is thought to occur when malfunctioning ovaries reduce blood estrogen levels. . Research Corporation Technologies (RCT RCT Randomized Controlled Trial RCT Regimental Combat Team (infantry regiment with their own artillery, engineers, medical and tanks) RCT Rollercoaster Tycoon RCT Randomized Clinical Trial RCT Rhondda Cynon Taff ), Endocare Inc. and Temple University participated in the investment. The CryoFluor technology uses uncontained, cold, fluid perfluorochemicals as the cryogenic medium. The liquid cryogenic technology performs rapid, complete and controllable cryoablation of tissues. This method overcomes the limitations of conventional probe-based cryosurgery cryosurgery (krī`ōsr'jərē), bloodless surgical technique using a supercooled probe to destroy diseased or superfluous tissue. devices and creates access to a variety of new minimally invasive surgeries minimally invasive surgery Laparoscopic surgery, see there. See Laparoscopic cholecystectomy. . CryoFluor has completed engineering and related preclinical activities for its first product, a device to treat abnormal uterine bleeding by ablating the lining of the uterus, or endometrial ablation Endometrial ablation is a medical procedure that is used to remove (ablate) or destroy the endometrial lining of a woman's uterus. This technique is most often employed for women who suffer from excessive or prolonged bleeding during their menstrual cycle but can not or do not wish . Abnormal uterine bleeding is responsible for more than 1 million office visits annually in the United States. Endocare, a publicly traded cryosurgical company in Irvine, Calif., has invested in the development of the CryoFluor endometrial ablation device. Endocare is providing engineering, fabrication fabrication (fab´rikā´sh  n),n the construction or making of a restoration. , manufacturing, regulatory documentation and oversight, clinical oversight and marketing strategy support. For the next 10 months, CryoFluor will focus on initial clinical cases in Mexico to determine safety and feasibility. The company will also prepare for a pivotal clinical trial in the United States. "This investment will provide CryoFluor with the resources to complete safety and efficacy studies of our lead device for endometrial ablation and prove the superiority of our technology to treat abnormal uterine bleeding," said David Jackson, Ph.D., CryoFluor president and chief operating officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. . "The data from this trial will allow the company to initiate a multi-center trial in the United States and ultimately bring improved care to patients with this condition." Previously employed as an investment professional with CryoFluor's primary seed-round investor, RCT, Jackson has been involved in managing CryoFluor's development program since its inception. Jackson's experience in medical technology development has helped advance several therapeutic and diagnostic technologies through early clinical studies. RCT formed CryoFluor with Temple University to develop the work of Temple researchers, Thomas H. Shaffer, Ph.D., Marla R. Wolfson, Ph.D. and Robert G. Stern, Ph.D. RCT, in Tucson, Ariz., is a technology investment and management company that provides early-stage funding and development for promising biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. companies and technologies. Endocare Inc. is an innovative medical device company focused on development of minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing devices for treatment of prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. and believes its proprietary technologies have broad applications across a number of markets, including ablation of tumors in the kidney, lung, liver and bone. |
|
|||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion